Abstract: The present invention relates to an aerosol composition for forming a preferably hydrated membrane which after vaporizing comprises as least one hydrophobic phase containing at least one film-forming polymer at least partly solubilized in an organic solvent system. The polymer is selected from hydrophobic polyaminoacids, preferably from the polyaminoacids obtained from at least one of the amino acids alanine, valine, leucine, isoleucine, proline, methionine, phenylalanine, tryptophan, aspartic and glutamic acid esters, or the derivatives thereof. The compositions also comprises as least one hydrophilic phase, and at least one propellant. The preferably hydrated membrane formed by vaporizing this composition, the application of the composition and of the preferably hydrated membrane as a dressing, are also disclosed.

Abstract: An aerosol formulation of an aerosol propellant and a base form of a narcotic drug selected from the group consisting of fentanyl, sufentanil and remfentanyl is provided. Such a formulation allows for the drug to be dissolved within the propellant and used within a device which does not require the use of a lubricant. Formulations are also disclosed which include lubricants, wherein the lubricant and propellant are both either polar or both non-polar. Thus, the lubricant component does not act as a solvent or cosolvent, but rather acts as a lubricant for the valve used for dispersing the formulation to a patient. Typical non-polar propellants include chlorofluorocarbons, which are typically used in connection with non-polar lubricants such as saturated vegetable oils, e.g. fractionated coconut oils. Typical polar propellants include hydrofluoroalkanes, which are typically used in connection with polar lubricants such as polyethylene glycols.

Abstract: The present invention is concerned with the use of starch containing amylose as a complexant with iodine for preparing dry powder pharmaceutical formulations useful in the preparation of capsules or tablets. The helical structure of the amylose molecule and its ability to complex with smaller molecules including iodine make starch (amylose) a desirable vehicle for the administration of iodine (I.sub.2) as a dry powder formulation in capsule or tablet form. These pharmaceutical formulations are particularly useful in the treatment of or the prevention of iodine deficiency diseases including breast dysplasia, breast cancer, endometriosis, premenstrual syndrome, ovarian cysts and radiation sickness from nuclear fallout.

Abstract: The present invention relates to therapeutic methods for treating diseases characterized by an accumulation of high molecular weight DNA in mucous, thereby contributing to the viscosity of the mucous. Such diseases include cystic fibrosis and chronic bronchitis. Treatment includes administration of weak organic acids to promote acidification of cells and consequently apoptosis-induced DNA fragmentation. The invention also relates to therapeutic apparatus for administering the acid compositions.

Abstract: The invention provides a method for enhancing learning in a person by the administration of a mixed-floral odorant. The odorant can be used as an adjuvant to improve learning and as an aid in education, and for rehabilitation of patients diagnosed with pathologically-induced learning disabilities.

Abstract: A stable solution, cream, salve, or spray composition containing chlorine dioxide and a phosphate, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices brought about by any of leukoplakia, hairy leukoplakia, vaginitis, endometriosis, Candida Albicans, Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Pseudomonades, Candida species, and leukoplakia vulvae. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.

Abstract: The invention relates to the use as sole or additional foaming agent in aqueous compositions for treating the skin or the hair, which are packaged in an aerosol device and are capable of forming a foam after expansion into the air, of a terpolymer consisting of 25 to 90% of vinyl lactam, of 1 to 55% of unsaturated carboxylic acid and of 1 to 20% of alkyl acrylate or methacrylate containing at least 6 carbon atoms, and to cosmetic or dermatological compositions packaged as an aerosol and forming a foam in the air, containing the terpolymer.

Abstract: Aqueous nasal spray compositions containing:0.001-2% by weight/volume of a medicament selected from the group consisting of chlorpheniramine maleate, oxymetazoline hydrochloride and mixtures thereof;0.50 to 15.00% by weight/volume of a water soluble polymer selected from the group consisting of polyvinylpyrrolidone having an average molecular weight of about 10,000 to 360,000 and mixtures thereof;2.5 to 10.00% by weight/volume of polyethylene glycol;1.00 to 10.00% by weight/volume of a moisturizing agent other than polyethylene glycol;0.01 to 0.05% by weight/volume of disodium edetate;0.001 to 0.3% by weight/volume of an antimicrobial preservative;0.20 to 5.00% by weight/volume of an aromatic alcohol;a sufficient amount of a pharmaceutically acceptable buffer to maintain the pH of the composition within the range of about 4.0 to 8.0; andQS water.

Abstract: Aerosol formulations for oral inhalation containing flunisolide dispersed in HFC 134a and/or HFC 227 which are free of chlorofluorocarbons and surfactants, and contain little or no ethanol, are disclosed. Metered dose inhalers suitable for delivering such formulations are also disclosed.

Abstract: Methods and compositions that provide for the long-term adhesion and slow-release of various bioactive agents on the surface of human skin utilize siloxane bridging agents activated for reaction with the skin surface which bind the bioactive agent to the skin surface. Since the topical agent remains bound to the continuously renewing epidermis, safety is enhanced for many bioactive agents. Slight modifications of the siloxane bridging compounds or bioactive agents allows for more or less adhesion to the skin, controlling the degree of release of the agent. Skin treatments according to the invention can provide enhanced repellency to microorganisms, insect bites, sun, water, poison ivy/oak, and other skin irritants, and other effects such as artificial skin coloring and administration of topical drugs, among others.

Abstract: Aerosol formulations for oral inhalation containing triamcinolone acetonide and HFC 134a and/or HFC 227 as a propellant which are free of chlorofluorocarbons and surfactants are disclosed.

Abstract: Homogeneous antimicrobial compositions and antimicrobial wet wipes and lotions which include the antimicrobial compositions are described. The homogeneous antimicrobial composition includes at least about 50 weight percent water based on a total weight of the composition and an effective amount of a hydrophobic antimicrobial agent which is uniformly dispersed in the composition. The antimicrobial wet wipe includes from about 150 to about 600 weight percent of the antimicrobial composition based on the dry weight of the wipe. The homogenous antimicrobrial composition may include, based upon the total weight of the composition, (a) from about 0.01 to about 3.0 weight percent of a hydrophobic antimicrobrial agent; (b) from about 1.0 to about 15.0 weight percent of an amide; (c) from about 1.0 to about 30.0 weight percent of a surfactant; and (d) from about 50 to about 98 weight percent water.

Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by a method whereby an aerosolized insulin formulation is delivered to a patient's lungs and the rate at which the insulin is absorbed into the blood is increased by the use of monomeric insulin and/or an inhale-exhale breathing maneuver. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The rate of absorption is enhanced by the monomeric form of insulin and by instructing the patient to inhale maximally and thereafter exhale maximally. This maneuver causes a spike in the rate at which insulin enters the circulatory system thereby increasing the rate at which glucose is removed from the circulatory system. The insulin or insulin analog may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.

Abstract: A method for enhancing penetration of a therapeutic or prophylactic agent in a host in need of the topical administration thereof which comprises applying to the epithelium of the host, an effective amount of one or more penetration enhancing epithelial sterols and the therapeutic or prophylactic agent.

Abstract: The invention relates to active substance combinations which consist of at least one polypeptide with the biological action of fibroblast growth factors and of at least one cationic polyelectrolyte. These combinations permit improved dosage of the FGF activity. The invention also relates to a method of treating wounds, burns, skin ulcers, diabetic gangrene, mucosal ulcers and lesions, skin donation and transplantation sites, or surgical wounds by administering a peptide having FGF activity with an amount of cationic polyelectrolyte which is effective to decrease non-specific binding of the peptide having FGF activity.

Abstract: A method for treating photodermatitis, thermal burn, decubitus ulcer, or herpes zoster by topically applying a composition comprising a water soluble vinyl polymer gel or lotion comprising 1H-imidazole-4-ethanamine, phosphate uniformly mixed therewith to the affected areas.

Abstract: A method for providing pain relief includes topically applying to skin tissue an effective amount of higher homologs of isoparaffins, ranging from about C.sub.12 to C.sub.18. Compositions of the present invention include, with the isoparaffins in a mixture, at least one from the group consisting of salicylate, capsaicin, camphor, and menthol. Other constituents may be added for form creams or lotions.

Abstract: A method for preparation of a shelf-stable precursor solution used to prepare a vaccine delivery system and useful for remote encapsulation of active ingredients is described. The vaccine delivery system utilizes solvent dilution microcarriers into which pathogen subunits are incorporated for delivering antigens to mucosal sites for stimulating imunoglobulin production.

Abstract: A microcapsule contains a pharmaceutically effective amorphous water-soluble 2-piperazinone-1-acetic acid compound or salt thereof and a polymer binder and a method of preparing said microcapsule. The microcapsule is produced by dispersing in an aqueous phase a dispersion of the amorphous water-soluble 2-piperazinone-1-acetic acid compound or salt thereof in a solution of a polymer in an organic solvent to give an s/o/w type emulsion and subjecting the emulsion to in-water drying. The sustained-release microcapsule entraps 2-piperazinone-1-acetic acid compound or the salt thereof, as a drug, in high concentration, and in reducing the initial release of the drug, thereby reducing undesirable side effects of the drug.

Abstract: Methods of hydrating lung mucous secretions in the lungs of a subject are disclosed. The methods involve administering benzamil or phenamil to the lungs of the subject in an amount effective to hydrate lung mucous secretions. The administering step is preferably carried out by inhalation administration. The method is useful in the treatment of diseases such as cystic fibrosis and chronic bronchitis.